CN1069070A - Method for preparing gamma-linolenic acid and biological preparation mainly containing gamma-linolenic acid - Google Patents
Method for preparing gamma-linolenic acid and biological preparation mainly containing gamma-linolenic acid Download PDFInfo
- Publication number
- CN1069070A CN1069070A CN 91106190 CN91106190A CN1069070A CN 1069070 A CN1069070 A CN 1069070A CN 91106190 CN91106190 CN 91106190 CN 91106190 A CN91106190 A CN 91106190A CN 1069070 A CN1069070 A CN 1069070A
- Authority
- CN
- China
- Prior art keywords
- linolenic acid
- linolenic
- preparation
- strain
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 title 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 title 2
- 229960002733 gamolenic acid Drugs 0.000 title 2
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 26
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000004519 grease Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 231100000219 mutagenic Toxicity 0.000 claims description 4
- 230000003505 mutagenic effect Effects 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 3
- 241001290628 Cunninghamella echinulata Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 229930003756 Vitamin B7 Natural products 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 238000012807 shake-flask culturing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- SWHAQEYMVUEVNF-UHFFFAOYSA-N magnesium potassium Chemical compound [Mg].[K] SWHAQEYMVUEVNF-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 235000019157 thiamine Nutrition 0.000 claims 1
- 150000003544 thiamines Chemical class 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 231100000350 mutagenesis Toxicity 0.000 abstract description 3
- 238000002703 mutagenesis Methods 0.000 abstract description 3
- 239000003208 petroleum Substances 0.000 abstract description 3
- 239000003124 biologic agent Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract 2
- 241000235555 Cunninghamella Species 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002179 ephedrine Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009377 nuclear transmutation Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical group CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000235575 Mortierella Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 244000196929 Oenothera glazioviana Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- -1 amino acids polysaccharide Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- QENHCSSJTJWZAL-UHFFFAOYSA-N magnesium sulfide Chemical compound [Mg+2].[S-2] QENHCSSJTJWZAL-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a preparation method of r-type ephedrine and a biological preparation mainly comprising the same, belonging to the field of microorganisms. The main characteristic is that it selects and uses Cunninghamella spinosa, through microwave and ultraviolet mutagenesis treatment, a transmutation strain with high yield of lipid and r-linolenic acid is obtained, then through shake flask fermentation or 500 liter jar fermentation, a biological preparation mainly containing r-linolenic acid is prepared. The oil ester of the r-linolenic acid can be obtained after the treatment by a petroleum ether extraction method. The biological agent obtained by the present invention can be used in the fields of medicine, food, and the like.
Description
The present invention system belongs to microorganism field, and promptly providing a kind of r-linolenic acid to reach with it is the preparation method and the biotechnological formulation of the biotechnological formulation of major ingredient.
R-linolenic acid (r-Llnotenlc acld) is a kind of C 18 unsaturated fatty acid, is called for short GLA.GLA is the precursor with highly bioactive prostaglandin(PG) (prostay landlns), and it has the important physical effect in body.Therefore, over past ten years, the attention that the research of r-linolenic acid unsaturated fatty acids and application are subjected to countries in the world.Oenothera oil is present more welcome control high blood cholesterol drug, it is by extracting in the seed of Radix Oenotherae erythrosepalae, and its main component is a linolic acid, secondly is the r-linolenic acid, because linoleic acid content is higher than r-linolenic acid 7-8 doubly, linolenic physiological function of r-and drug effect have therefore been limited.In addition, since the influence of natural condition, the resource-constrained of root of Redsepal Eveningprimrose.Therefore, countries such as day, English have adopted microbial method to produce GLA, mainly utilize mortierella (Morteralla), head mold (Rhlzopus) suitability for industrialized production r-linolenic acid, but the meta-bolites and the cell content that obtain can not used thereupon.
In order to solve the Microbial resources of natural resources deficiency, development and use China, the invention provides a kind of r-linolenic acid and be the preparation method of the biotechnological formulation of major ingredient, and the tunning (comprising by product) of preparation is applied to fields such as medical science and food with it.
Principal character of the present invention is that it is made up of following operation: 1, separate the cunninghamella echinulata original strain from the wild-type strain that produces unsaturated fatty acids; 2, through microwave treatment 10-20 second, shake-flask culture is selected the high bacterial strain of r-linolenic acid output; 3, carry out mutagenic treatment with ultraviolet irradiation, select through shaking bottle again; 4, at PH:6-5.5, under the temperature 26-30 ℃ of condition, is carbon source with strain culturing at, acetate close with glucose or sucrose, starch, sugar, with sulfuric acid or urea, peptone is nitrogenous source, and contain vitamin H, in the matrix of VITAMIN and potassium magnesium inorganic salt oscillation and fermentation 96-144 hour or adopt the sucrose of 6-10% or sugar close be carbon source, C: N=30: 1, temperature is 26-28 ℃, and stirring velocity is that 200 rev/mins 500 liter jars fermented 140-150 hour; 5, filtration, washing, drying.Can obtain the r-linolenic acid by preparation method provided by the present invention is major ingredient, is equipped with secondary meta-bolites-polysaccharide, each seed amino acid, polyoxide dismutase and the VITAMIN of mutagenic fungi, B
1B
2Biotechnological formulation with E.In addition the product that aforesaid method obtained is handled with sherwood oil, can be extracted the linolenic grease of contained r-.
Original strain-cunninghamella echinulata of mentioning among the above-mentioned preparation method, a plant height that obtains after microwave and ultraviolet mutagenesis processing produces lipid and the higher mutagenic fungi of r-linolenic acid ability, this bacterial strain was cultivated 2 days under 28 ℃ of temperature in the murphy juice nutrient agar, colony diameter 3.0-4.0cm, mycelia is loose, the cotton wool shape, white, there is part white conidium to form, cultivated 4 days, colony diameter 4.0-6.0cm, mycelia is by leucismus lime look, and conidium is the lark or the colour of camel's hair, cultivates 6 days, mycelia is covered with incubator, be lark or drabon look, sophisticated conidium is lark or tawny, and as seen microscopically is observed, the flourishing multi-branched of vegetative hyphae, diameter 10-20 micron, conidiophore is upright, and the bubble bundle that the branch top forms has stigma, formed the conidium of garden type or the very thin thorn of ellipse garden type band on the stigma, diameter 10-15 micron.
Below by embodiment in detail the linolenic preparation method of r-provided by the present invention and biotechnological formulation and preparation method thereof are described in detail.
The preparation method of the embodiment 1-linolenic shake flask fermentation of r-
(1) the r-linolenic acid produces the screening of bacterium
Take all factors into consideration according to the speed of growth, lipid and r-linolenic acid content, select the cunninghamella echinulata bacterial classification;
(2) microwave and ultraviolet radiation mutagenesis are handled;
With the spore of the original strain that filters out, in microwave oven, handled for 15 seconds, shake-flask culture is measured lipid and r-linolenic acid content then, selects r-linolenic acid bacterial strain, uses uviolizing again, thereby has obtained high yield lipid, the linolenic bacterial strain of r-.
(3) shake flask fermentation
Above-mentioned bacterial strains is cultivated at glucose 4%, urea 0.12%, phosphorus Chinese hydrogen potassium (KH
2PO
4) 0.05 magnesium sulfide (MgSO
4.7H
2O) 0.025%, vitamins B, in the matrix of vitamin H trace, shaking culture is 4 days under 28-30 ℃ temperature;
(4) filtration, washing, drying
(5) obtain the linolenic grease of r-with the Petroleum ether extraction method.
The preparation method of embodiment 2-r-linolenic acid 500 liter jars fermentation
(1) (2) step is identical with embodiment 1,
(3) adopting the sucrose (or sugar is close) with 10% be carbon source, C: N=30: 1, and temperature is 28 ℃, stirs the speed of trembling and is 200 rev/mins 500 liter jars and ferment hour;
(4) (5) are also identical with embodiment 1.
One kind of embodiment 3-is biological agent of major ingredient and preparation method thereof with the r-linolenic acid.
Different need not to obtain the linolenic grease of r-with the Petroleum ether extraction method present embodiment with embodiment 1,2, but will be after filtration, washing, dried product directly be used for as biotechnological formulation, its major ingredient is the r-linolenic acid, and all the other are multiple meta-bolites and cell content.The concrete composition of biotechnological formulation provided by the present invention is: grease yield 31-36%, and r-linolenic acid content 12-13%, dry cell weight 25-27 grams per liter contains 20 multiple amino acids polysaccharide, many oxydase dismutase (SOD) and vitamins B in addition
1B
2Metabolism such as PP and E product.
What the present invention will obtain is main component with the r-linolenic acid, and the biotechnological formulation that the above-mentioned multiple meta-bolites of proportioning is made has carried out the toxicity and the test of pesticide effectiveness of bacterial strain.With various dose abdominal injection and filling stomach mode, to 70 small white mouses, carried out acute toxicity test, by testing to sample continuously of a large amount of animals of 251 days (small white mouse and big white mouse), growth, survival and death, routine blood test, liver function, renal function index to animal detect, and prove no chronic toxicity and cumulative toxicity.
Carry out the test of pesticide effectiveness by isolated rabbit and animal being raised for a long time institute, its result proves, biotechnological formulation provided by the present invention has anticoagulant, reduce plasma viscosity, improve blood middle-high density lipoprotein, the effect of triglyceride reducing, whole blood viscosity and hematocrit in addition, also has in improving hemorheology status and changing atherosclerosis.
Moreover, biotechnological formulation provided by the present invention also is used to 30 patient's clinical observations 3 months, the result proves that said preparation not only can reduce glycerine three pure and mild hematoblastic aggregations but also can make whole blood viscosity and cholesterol that tangible reduction is arranged, therefore, open up new approach to the control of cardiovascular and cerebrovascular diseases and (seen Appendix 1,2,3,4,5,6).
Advantages such as in sum as can be seen, it is simple that the linolenic preparation method of r-provided by the present invention has technology than prior art, and the bacterial classification source is abundant, prepared biotechnological formulation can be widely used in medical science, in the fields such as food.
Claims (4)
1, a kind of is the preparation method of the biotechnological formulation of major ingredient with the r-linolenic acid, it is characterized in that it is made up of following operation:
(1) from the wild-type strain that produces unsaturated fatty acids, separates the cunninghamella echinulata original strain;
(2) become processing thoroughly with uviolizing again second through microwave treatment 10-20, shake-flask culture is selected the high bacterial strain of r-linolenic acid output then;
(3) at PH:6-5.5, under the temperature 26-30 ℃ of condition, is carbon source with strain culturing at, acetate close with glucose or sucrose, starch, sugar, with thiamines or urea, peptone is a nitrogenous source, to contain vitamin H, in the matrix of VITAMIN and potassium magnesium inorganic salt, oscillation and fermentation 96-144 hour or to adopt close with the sucrose of 6-10% or sugar be carbon source, C: N-30: 1, temperature is that 28 ± 2 ℃ of stirring velocitys are 200 rev/mins 500 liter jars fermentation 140-150 ℃ hour.
(4) filtration, washing, drying.
2,, it is characterized in that best culture medium is according to the described preparation method of claim 1:
Glucose (or sucrose) 4-10%
Urea 0.12-0.5%
KH
2PO
40.025-0.08%
MgSO
47H
2O 0.025-0.05%
3, a kind of biotechnological formulation that is obtained by claim 1,2 described preparation methods is characterized in that it is a major ingredient with the r-linolenic acid, and the pair that is equipped with mutagenic fungi is for product polysaccharide, each seed amino acid, polyoxide dismutase and vitamins B
1B
2PP and E.
4, the linolenic preparation method of a kind of r-is characterized in that the product that the 4th procedure among the described preparation method of claim 1 obtains handled with sherwood oil and extracts the linolenic grease of contained r-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91106190A CN1035627C (en) | 1991-07-30 | 1991-07-30 | Preparation method of r-sub-anesthesia and biological preparation mainly comprising r-sub-anesthesia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91106190A CN1035627C (en) | 1991-07-30 | 1991-07-30 | Preparation method of r-sub-anesthesia and biological preparation mainly comprising r-sub-anesthesia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1069070A true CN1069070A (en) | 1993-02-17 |
| CN1035627C CN1035627C (en) | 1997-08-13 |
Family
ID=4907625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN91106190A Expired - Fee Related CN1035627C (en) | 1991-07-30 | 1991-07-30 | Preparation method of r-sub-anesthesia and biological preparation mainly comprising r-sub-anesthesia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1035627C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329519C (en) * | 2006-03-29 | 2007-08-01 | 王景恒 | Gamma-linolenic acid dry microbial powder enriched with organic celenium and its producing process |
| CN100348514C (en) * | 2005-03-29 | 2007-11-14 | 华中科技大学 | Deep-processing method of using starch watewater |
| CN102676594A (en) * | 2012-05-25 | 2012-09-19 | 厦门大学 | Preparation method of gamma-linolenic acid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2052564T3 (en) * | 1986-07-08 | 1994-07-16 | Suntory Ltd | PROCEDURE FOR THE PRODUCTION OF BISHOMO-GAMMA-LINOLENIC ACID AND EICOSAPANTEONIC ACID. |
| JP2746371B2 (en) * | 1987-12-21 | 1998-05-06 | サントリー株式会社 | Bishomo-γ-linolenic acid and method for producing lipid containing the same |
| US5093249A (en) * | 1989-05-24 | 1992-03-03 | Idemitsu Petrochemical Co., Ltd. | Process for production of dihomo-γ-linolenic acid and inhibitor for unsaturation reaction at Δ5-position of fatty acid |
-
1991
- 1991-07-30 CN CN91106190A patent/CN1035627C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100348514C (en) * | 2005-03-29 | 2007-11-14 | 华中科技大学 | Deep-processing method of using starch watewater |
| CN1329519C (en) * | 2006-03-29 | 2007-08-01 | 王景恒 | Gamma-linolenic acid dry microbial powder enriched with organic celenium and its producing process |
| CN102676594A (en) * | 2012-05-25 | 2012-09-19 | 厦门大学 | Preparation method of gamma-linolenic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1035627C (en) | 1997-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen | Modern solid state fermentation | |
| DE69621663T2 (en) | Process for the preparation of arachidonic acid | |
| JP6807329B2 (en) | Methods and applications for culturing ω-7 fatty acid compounds and yellow-green algae to produce the compounds | |
| Santos et al. | A symbiotic gas exchange between bioreactors enhances microalgal biomass and lipid productivities: taking advantage of complementary nutritional modes | |
| CN1986822A (en) | Crypthecodinium connii fermenting process for producing docosahexaenoic acid grease | |
| Agwa et al. | Bioethanol production from Chlorella vulgaris biomass cultivated with plantain (Musa paradisiaca) peels extract | |
| CN100469890C (en) | Method for preparing conjugated linoleic acid | |
| CN104429604A (en) | Sparassis crispa liquid strain culture medium and culture method | |
| CN113308387B (en) | Bacterial strain for co-production of unsaturated fatty acid and carotenoid and application thereof | |
| CN101113410B (en) | Mortierella alpina and application thereof | |
| Ramaraj et al. | Stimulation of natural enzymes for germination of mimosa weed seeds to enhanced bioethanol production | |
| CN104212846A (en) | Method for producing DHA (docosahexenoic acid) by using cheap bean pulp as nitrogen source for fermenting schizochytrium | |
| CN101805760A (en) | Method for producing microbial oil comprising arachidonic acid | |
| CN1035627C (en) | Preparation method of r-sub-anesthesia and biological preparation mainly comprising r-sub-anesthesia | |
| CN107739721A (en) | Produce bacillus sp.W2017 and its application of agar-agar digestive enzyme | |
| CN106047956B (en) | A method of the Penicillium citrinum Asc2-4 that grown nonparasitically upon another plant altogether using ascidian fermentation preparation is rich in the grease of gamma-Linolenic acid | |
| CN108157065A (en) | A kind of mycelial cultural method of Antrodia camphorata and its application | |
| CN102703332B (en) | Bacterial strain for producing arachidonic acid grease and application thereof | |
| CN102329833A (en) | Method for producing sophorose ester through fermenting waste molasses and waste glycerin | |
| CN112280696B (en) | Culture method for improving oil content of saccharomyces cerevisiae by maintaining ultralow-concentration organic carbon source and application of culture method | |
| CN109593627A (en) | A kind of electric field-enhanced brewage process of sea-buckthorn Chinese wolfberry health-care fruit wine | |
| CN108949725A (en) | The production of complex enzyme formulation and purifying process | |
| CN115404246A (en) | Microbial oil rich in Sn-2DHA, and preparation method and application thereof | |
| CN106538420B (en) | A kind of jellyfish cultivation bait fertilizer and its application | |
| CN105505903B (en) | Induction sugar and cellulase induction synthetic method are prepared using yeast cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |